LONDON, Nov. 30, 2011 /PRNewswire/ -- Cognizant (NASDAQ: CTSH), a leading provider of consulting, technology, and business process outsourcing services, today announced a multi-year agreement with AstraZeneca to deliver comprehensive biostatistics and medical reporting services to generate clinical study reports.
Under the agreement, Cognizant will provide centralized statistical programming, statistical analysis, medical writing, and document publishing services, spanning the entire chain of clinical data reporting from case report forms to clinical study reports. This will enable AstraZeneca to increase operational efficiency, reduce cycle times, and optimize costs. AstraZeneca will continue to own and manage key scientific and medical activities associated with the design of clinical trial programs, and the interpretation of data from them.
Cognizant will leverage its proprietary Web 2.0-based platform, Cognizant 2.0, to support knowledge sharing and collaboration across global teams, allowing clinical studies across different countries to be managed simultaneously, and delivering significant productivity benefits to AstraZeneca.
"Cognizant will help us streamline our clinical development operations. This is key to our business transformation aimed at achieving greater efficiency, agility, flexibility, and global competitiveness -- all of which are crucial to clinical trials and development of new drugs," said Karin Wingstrand, Vice President and Head of Clinical Development at AstraZeneca. "Leveraging Cognizant's IT and business process expertise allows AstraZeneca to focus more time, energy, and investment on those clinical activities that will make a difference in developing innovative medicines more quickly for patients."
"We are pleased to have been selected by AstraZeneca to provide biostatistics and medical reporting services," said Krish Venkat, Senior Vice President of the Healthcare and Life Sciences practice at Cognizant. "We are strongly committed to leveraging the domain and process knowledge of our experienced biostatisticians and medical writers to support AstraZeneca through improved decision-making, process standardization, consistency of delivery, and cost savings, which they can reinvest to support the fast, innovative, and efficient development of their R&D programs."
This agreement further expands the services that Cognizant provides to AstraZeneca. AstraZeneca first engaged Cognizant in 2004 to provide business process and technology solutions spanning discovery, clinical, manufacturing, and commercial operations.